EA200701995A1 - Способы уменьшения кальцификации - Google Patents

Способы уменьшения кальцификации

Info

Publication number
EA200701995A1
EA200701995A1 EA200701995A EA200701995A EA200701995A1 EA 200701995 A1 EA200701995 A1 EA 200701995A1 EA 200701995 A EA200701995 A EA 200701995A EA 200701995 A EA200701995 A EA 200701995A EA 200701995 A1 EA200701995 A1 EA 200701995A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
reducing calcification
calcification
reducing
calcimimetics
Prior art date
Application number
EA200701995A
Other languages
English (en)
Inventor
Дейвид Мартин
Хуан Мариано Портилло
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA200701995A1 publication Critical patent/EA200701995A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Настоящее изобретение относится к способам лечения кальцификации сосудов у пациентов с использованием кальцимиметиков.
EA200701995A 2005-03-17 2006-03-17 Способы уменьшения кальцификации EA200701995A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66327005P 2005-03-17 2005-03-17
PCT/US2006/009683 WO2006102061A2 (en) 2005-03-17 2006-03-17 Methods of decreasing calcification

Publications (1)

Publication Number Publication Date
EA200701995A1 true EA200701995A1 (ru) 2008-02-28

Family

ID=36588866

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701995A EA200701995A1 (ru) 2005-03-17 2006-03-17 Способы уменьшения кальцификации

Country Status (15)

Country Link
US (1) US20060276534A1 (ru)
EP (1) EP1858553A2 (ru)
JP (1) JP2008533170A (ru)
KR (1) KR20070116817A (ru)
CN (1) CN101184508A (ru)
AU (1) AU2006227429A1 (ru)
BR (1) BRPI0609524A2 (ru)
CA (1) CA2601669A1 (ru)
CR (1) CR9439A (ru)
EA (1) EA200701995A1 (ru)
IL (1) IL185757A0 (ru)
MX (1) MX2007011153A (ru)
NO (1) NO20075304L (ru)
WO (1) WO2006102061A2 (ru)
ZA (1) ZA200707639B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006127941A2 (en) * 2005-05-23 2006-11-30 Teva Pharmaceutical Industries Ltd. Amorphous cinacalcet hydrochloride and preparation thereof
JP2009512710A (ja) * 2005-10-21 2009-03-26 アムジエン・インコーポレーテツド Ｉｌ−１阻害剤を用いて血管石灰化を抑制する方法
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
EP1828098A1 (en) * 2005-11-22 2007-09-05 Teva Pharmaceutical Industries Ltd Crystal forms of cinacalcet hci and processes for their preparation
CA2645494C (en) * 2006-03-23 2016-01-12 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
CN101437490A (zh) * 2006-04-20 2009-05-20 安美基公司 稳定乳液配方
JP5027214B2 (ja) * 2006-04-27 2012-09-19 テバ ファーマシューティカル インダストリーズ リミティド シナカルセット塩基の調製法
KR20080011320A (ko) * 2006-04-27 2008-02-01 테바 파마슈티컬 인더스트리즈 리미티드 시나칼셋 염기의 제조 방법
EP2069285A1 (en) * 2006-06-27 2009-06-17 Sandoz AG Amorphous form of cinacalcet
WO2008063645A1 (en) * 2006-11-20 2008-05-29 Teva Pharmaceutical Industries Ltd. Process for preparing cinacalcet
US8119693B2 (en) * 2007-05-08 2012-02-21 Sanford-Burnham Medical Research Institute Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
WO2009025792A2 (en) * 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
WO2013041205A1 (de) 2011-09-19 2013-03-28 Pyxirion Pharma Gmbh Neue therapeutische konzepte zur behandlung von gefässerkrankungen
US20130085121A1 (en) * 2011-09-30 2013-04-04 Jianguo Wang Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
EP2776129B2 (en) * 2011-11-10 2020-06-17 Kai Pharmaceuticals, Inc. Compositions for use in the treatment of chronic kidney disease-mineral bone disorder characterized by soft tissue calcification
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
WO2020084349A1 (en) * 2018-10-25 2020-04-30 Opko Ireland Global Holdings, Ltd Methods of treatment with mixed metal compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6313146B1 (en) * 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
DE122005000033I2 (de) * 1994-10-21 2006-11-23 Nps Pharma Inc Kalzium-Receptor aktive Verbindungen
PT907631E (pt) * 1996-05-01 2003-10-31 Nps Pharma Inc Compostos inorganicos activos como receptores de ioes
WO1998001417A1 (fr) * 1996-07-08 1998-01-15 Kirin Beer Kabushiki Kaisha Composes actifs comme recepteurs du calcium
TW483881B (en) * 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
JP2002527414A (ja) * 1998-10-14 2002-08-27 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド １，２−ジ置換シクロプロパン
US6551990B2 (en) * 1998-12-07 2003-04-22 University Of Washington Methods of inhibiting ectopic calcification
BRPI0015061B8 (pt) * 1999-10-19 2021-05-25 Geltex Pharma Inc comprimido revestido tendo alta dosagem de cloridrato de sevelamer
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US20050288377A1 (en) * 2004-06-14 2005-12-29 Cantor Thomas L Use of calcimimetic as an adynamic bone disease related treatment

Also Published As

Publication number Publication date
BRPI0609524A2 (pt) 2011-10-18
EP1858553A2 (en) 2007-11-28
CR9439A (es) 2007-11-23
IL185757A0 (en) 2008-01-06
WO2006102061A2 (en) 2006-09-28
NO20075304L (no) 2007-11-29
JP2008533170A (ja) 2008-08-21
ZA200707639B (en) 2008-06-25
MX2007011153A (es) 2007-12-12
CA2601669A1 (en) 2006-09-28
AU2006227429A1 (en) 2006-09-28
KR20070116817A (ko) 2007-12-11
CN101184508A (zh) 2008-05-21
WO2006102061A3 (en) 2006-12-14
US20060276534A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
EA200701995A1 (ru) Способы уменьшения кальцификации
NL301145I2 (nl) Tirbanibulin
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
EA201170521A1 (ru) Новые соединения
NO20092637L (no) Fremgangsmater for behandling
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
EA201001639A1 (ru) Композиции и способы их получения и применения
MX2007016322A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EA201171367A1 (ru) Винилиндазолильные соединения
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
MA32544B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
EA201071221A1 (ru) Гетероциклические соединения
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
ATE538799T1 (de) Zusammensetzungen zur behandlung von haarverlust